IMMUNOPRECISE ANTIBODIES LTD

Inactive Instrument

Highlights Immunoprecise Antibodies Ltd Other OTC

Equities

CA87588T1030

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

ImmunoPrecise Antibodies Ltd. Announces an Expansion of Its LENSai Platform	22/04	CI
ImmunoPrecise Antibodies And InterSystems Partner To Leverage AI In Life Sciences, Transforming Patient Care With Accelerated Discovery And Delivery Of Treatments	12/04	CI
ImmunoPrecise Antibodies Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended January 31, 2024	14/03	CI
ImmunoPrecise Antibodies Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended October 31, 2023	14/12	CI
Jobs Data in Focus as Exchange-Traded Funds, Equity Futures Lean Higher Pre-Bell Wednesday	06/12	MT
ImmunoPrecise Antibodies Develops the Lensai's Integrated Intelligence Platform Powered by Hyft Technology	20/23/20	CI
ImmunoPrecise Antibodies Ltd. Reports Earnings Results for the First Quarter Ended July 31, 2023	14/23/14	CI
ImmunoPrecise Antibodies Ltd. Announces Board Changes	06/23/06	CI
ImmunoPrecise Antibodies Ltd. Reports Earnings Results for the Full Year Ended April 30, 2023	11/23/11	CI
ImmunoPrecise Antibodies Ltd. Introduces Transformative AI-Driven Rapid Therapeutic Screening Platform	06/23/06	CI
ImmunoPrecise Enters Into Research Collaboration, License Option Agreement With Xyphos Biosciences	30/23/30	MT
ImmunoPrecise’s Subsidiary Talem Enters into Exclusive Research Collaboration and License Option Agreement with Astellas	30/23/30	CI
ImmunoPrecise Antibodies Ltd. Announces European Patent Office to Grant Biokey’S Patent Application for Foundational HYFT® Technology	27/23/27	CI
ImmunoPrecise Antibodies Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended October 31, 2022	15/22/15	CI
IPA Subsidiary BioStrand, BriaCell in AI Collaboration and License Agreement to Discover and Develop Anti-Cancer Antibodies	30/22/30	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

+39.41% on our US portfolio vs. 25.67% on the S&P 500 net Total Return

Replicate our performance

fermer